Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Basiliximab induction in ABO-incompatible pediatric liver transplantation
ChiCTR1800019322Phase 4Not yet recruiting
- Sponsor
- Tianjin First Central Hospital
- Start
- Nov 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of basiliximab in Hepatic transplant rejection (LTR) (2 arms), sponsored by Tianjin First Central Hospital. Primary endpoints: Incidence of rejection, Graft survival rate and 4 more. Planned start Nov 2018; status: not yet recruiting.
02
Drugs
basiliximab
03
Conditions
Hepatic transplant rejection (LTR)
Beyond the preview
Go deeper on ChiCTR1800019322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800019322.